Hammond K B
Clin Toxicol. 1977;10(2):159-83. doi: 10.3109/15563657708987965.
In this era of polypharmacy, the incidence of adverse reactions due to drug therapy has increased alarmingly since the precise effects on the metabolism of a drug given in combination with other drugs can never be predicted with certainty. Inadequate therapy due to insufficient medication or to factors which diminish absorption or enhance metabolism may be equally undesirable. The consequences to patients in terms of increased morbidity and financial cost of prolonged hospitalization may be considerable. For pediatric patients, particularly in the newborn period, these hazards may be much more dangerous. There is a need for more investigation into the validity of procedures in current use for the determination of drug levels in biologic fluids and into the interpretation of the values they produce. In addition clinical chemists and clinical pharmacologists are faced with the challenge of defining those drugs for which blood level information would be advantageous and developing rapid, sensitive, and accurate assays which can be performed by the routine clinical laboratory. The day may be not too far away when a major proportion of the workload of the clinical laboratory consists of assays primarily designed as an aid to therapy rather than diagnosis.
在这个多种药物联合使用的时代,由于药物治疗导致的不良反应发生率急剧上升,因为与其他药物联合使用时,一种药物对新陈代谢的确切影响永远无法准确预测。由于用药不足或导致吸收减少或代谢增强的因素而导致的治疗不充分同样不可取。就发病率增加和延长住院时间的经济成本而言,对患者的影响可能相当大。对于儿科患者,尤其是新生儿,这些风险可能更加危险。有必要对目前用于测定生物体液中药物水平的程序的有效性及其所产生数值的解释进行更多研究。此外,临床化学家和临床药理学家面临着界定哪些药物的血药浓度信息会有帮助,并开发可由常规临床实验室进行的快速、灵敏和准确检测方法的挑战。临床实验室的大部分工作量主要用于辅助治疗而非诊断的检测方法的那一天可能并不遥远。